SHORT MINI-FUTURE - ROCHE GS Share Price

Certificat

DE000VV1F1P6

Market Closed - Deutsche Boerse AG 18:42:11 14/06/2024 BST
10.43 EUR -0.57% Intraday chart for SHORT MINI-FUTURE - ROCHE GS
Current month-12.43%
1 month-16.83%
Date Price Change
14/06/24 10.43 -0.57%
13/06/24 10.49 -1.96%
12/06/24 10.7 -2.01%
11/06/24 10.92 -1.80%
10/06/24 11.12 +2.77%

Delayed Quote Deutsche Boerse AG

Last update June 14, 2024 at 06:42 pm

More quotes

Static data

Product typeKnock-Out with Stop Loss
Buy / SellPUT
Underlying ROCHE HOLDING AG
IssuerLogo Issuer Vontobel Vontobel
WKN VV1F1P
ISINDE000VV1F1P6
Date issued 22/04/2022
Strike 347.8 CHF
Maturity Unlimited
Parity 10 : 1
Emission price 2.22
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 14.49
Lowest since issue 1.26

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
247.6 CHF
Average target price
278.1 CHF
Spread / Average Target
+12.30%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW